Pulse Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on October 11, 2016, reporting events occurring on October 5, 2016. The filing addresses Item 5.02 regarding compensatory arrangements for Darrin R. Uecker, the Company's President and Chief Executive Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on executive compensation adjustments.
Material Changes
The Company amended Mr. Uecker's employment agreement, originally executed on September 8, 2015. Key changes include:
- Deferral of Post-IPO Grant: Mr. Uecker agreed to forgo a previously planned option grant (equal to 3% of post-IPO fully diluted equity at $4.00/share) until shareholders approve a new equity incentive plan or an increase in available shares.
- Immediate Option Grant: In exchange, Mr. Uecker received an option to purchase 187,286 shares of Common Stock, representing the share count he would have received post-IPO.
- Restricted Stock Grant: Mr. Uecker received a restricted stock grant valued at the difference between the original $4.00 exercise price and the exercise price on the date of the deferral, multiplied by 187,286 shares.
- Change of Control Provision: If a change of control occurs before the option grant vests while Mr. Uecker is employed, he is entitled to a cash bonus equal to the consideration for 187,286 vested options at a $4.00 exercise price.
Management Commentary and Risks
The Compensation Committee and Board of Directors stated that the amendment does not materially change the value of the compensation originally afforded Mr. Uecker. The filing incorporates the full text of the Amendment as Exhibit 10.1.
Investor Verification Checklist
- Verify the exact exercise price of the new option grant and the resulting value of the restricted stock grant.
- Review the status of the Company's existing equity incentive plan and shareholder approval requirements.
- Confirm the vesting schedule for the 187,286 option shares and the restricted stock.
- Examine the full text of Exhibit 10.1 for additional terms regarding the change of control cash bonus.